dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Amaro Hosey, Kristopher |
dc.contributor.author | Danes Carreras, Immaculada |
dc.contributor.author | Vendrell Bosch, Lourdes |
dc.contributor.author | Alonso Garcia, Laura |
dc.contributor.author | Renedo Miro, Berta |
dc.contributor.author | Gros Subias, Luís |
dc.contributor.author | Vidal Guitart, Xavier |
dc.contributor.author | Cereza García, María Gloria |
dc.contributor.author | Agustí Escasany, Maria Antònia |
dc.date.accessioned | 2021-12-27T13:14:28Z |
dc.date.available | 2021-12-27T13:14:28Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Amaro-Hosey K, Danés I, Vendrell L, Alonso L, Renedo B, Gros L, et al. Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service. Front Pharmacol. 2021 May;12:670945. |
dc.identifier.issn | 1663-9812 |
dc.identifier.uri | https://hdl.handle.net/11351/6732 |
dc.description | Reaccions adverses als medicaments; Hematologia; Pediatria |
dc.description.sponsorship | Funding Project PI16/02018, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF). |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Pharmacology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Hematologia oncològica |
dc.subject | Càncer - Tractament |
dc.subject | Medicaments - Efectes secundaris |
dc.subject.mesh | Antineoplastic Agents |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Hematologic Diseases |
dc.subject.mesh | /drug therapy |
dc.title | Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fphar.2021.670945 |
dc.subject.decs | antineoplásicos |
dc.subject.decs | /efectos adversos |
dc.subject.decs | neoplasias hematológicas |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.3389/fphar.2021.670945 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Amaro-Hosey K] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Danés I, Vendrell L, Vidal X, Agustí A] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Alonso L, Gros L] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Renedo B] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Cereza G] Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Fundació Institut Català de Farmacologia. Vall Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34025429 |
dc.identifier.wos | 000651753500001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F02018 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |